X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration brings together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's messenger RNA (mRNA) and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics for oncology.
Lead Product(s): CAR-M-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 14, 2023
Details:
CT-0525 is an ex vivo gene-modified autologous chimeric antigen receptor-monocyte (CAR-Monocyte) cellular therapy intended to treat solid tumors that overexpress human epidermal growth factor receptor 2 (HER2).
Lead Product(s): CT-0525
Therapeutic Area: Oncology Product Name: CT-0525
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2023
Details:
CT-0508 is a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M). It is being evaluated in a landmark Phase 1 multi-center clinical trial that focuses on patients with recurrent or metastatic HER2-overexpressing solid tumors.
Lead Product(s): CT-0508,Pembrolizumab
Therapeutic Area: Oncology Product Name: CT-0508
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
The combined company will develop Carisma's lead candidate CT-0508, a CAR-M cell therapy and will also accelerate the growth of company's platform and pipeline within and outside of oncology.
Lead Product(s): CT-0508,Pembrolizumab
Therapeutic Area: Oncology Product Name: CT-0508
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: Sesen Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 21, 2023
Details:
Vicineum (oportuzumab monatox) is an investigational locally administered recombinant fusion protein that targets epithelial cell adhesion molecule antigens on the surface of tumor cells to deliver Pseudomonas Exotoxin A.
Lead Product(s): Oportuzumab Monatox
Therapeutic Area: Oncology Product Name: Vicineum
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sesen Bio
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Merger December 29, 2022
Details:
Carisma is developing CT-0508 to target HER2-positive solid tumors. While its expression in normal tissues is low, HER2 is highly expressed in a wide range of solid tumors and plays an active role in both malignant transformation and tumor.
Lead Product(s): CT-0508
Therapeutic Area: Oncology Product Name: CT-0508
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
The first clinical application of this technology is CT-0508, a CAR-M cell therapy currently being evaluated by Carisma in a Phase 1 multi-center clinical trial with a lead target indication of advanced HER2+ solid tumors.
Lead Product(s): CT-0508
Therapeutic Area: Oncology Product Name: CT-0508
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sesen Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger September 21, 2022
Details:
The findings are the first clinical data of genetically engineered macrophages in humans and demonstrate that CT-0508 was well tolerated after infusion and there were no dose-limiting toxicities reported to date in the current study.
Lead Product(s): CT-0508
Therapeutic Area: Oncology Product Name: CT-0508
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2022
Details:
CT-0508 is HER2 targeted chimeric antigen receptor macrophage (CAR-M). In pre-clinical study it demonstrated ability to traffic into tumor, phagocytose and kill cancer cells, warm-up tumor microenvironment, and attract and activate cells of adaptive immune system.
Lead Product(s): CT-0508
Therapeutic Area: Oncology Product Name: CT-0508
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
Under the terms of agreement, the Carisma manufacturing process will be transferred to Novartis Cell Therapy Site in Morris Plains, U.S for manufacturing of the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors by CT-0508.
Lead Product(s): CT-0508
Therapeutic Area: Oncology Product Name: CT-0508
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
